Ritter Pharmaceuticals to Present at 20th Annual HC Wainwright Global Investment Conference on September 5, 2018
August 28 2018 - 1:31PM
Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter
Pharmaceuticals” or the “Company”), a developer of novel
therapeutic products that modulate the gut microbiome to treat
gastrointestinal diseases with an initial focus on the development
of RP-G28, a drug candidate with the potential to be the first
FDA-approved treatment for lactose intolerance, today announces
that the company’s CEO, Andrew Ritter, will be a featured presenter
at the 20th Annual HC Wainwright Global Investment conference on
September 5, 2018 at 4:40 PM ET in the Library at the St. Regis
Hotel in New York City.
Mr. Ritter will provide an overview of the
company’s clinical development program for RP-G28, business model
and growth strategy and will be available for one-on-one
meetings.
About Ritter
Pharmaceuticals
Ritter Pharmaceuticals, Inc.
(www.RitterPharma.com, @RitterPharma) develops novel therapeutic
products that modulate the gut microbiome to treat gastrointestinal
diseases. The company’s lead product candidate, RP-G28, has the
potential to become the first FDA-approved treatment for lactose
intolerance, a condition that affects millions of people worldwide.
RP-G28 is currently in Phase 3 clinical development. The company is
further exploring the therapeutic potential that gut microbiome
changes may have on treating/preventing a variety of diseases
including: gastrointestinal diseases, cancer, metabolic, and liver
disease.
Forward-Looking StatementsThis
press release may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
that express the current beliefs and expectations of Ritter
Pharmaceuticals’ management, including statements regarding its
Phase 3 pivotal clinical trial for RP-G28 for the treatment of
lactose intolerance and other research and development initiatives
of the Company. Any statements contained herein that do not
describe historical facts are forward-looking statements that are
subject to risks and uncertainties that could cause actual results,
performance and achievements to differ materially from those
discussed in such forward-looking statements. Factors that could
affect our actual results are included in the periodic reports on
Form 10-K and Form 10-Q that we file with the Securities and
Exchange Commission. These forward-looking statements are made only
as of the date hereof, and the Company undertakes no obligation to
update or revise the forward-looking statements, except as
otherwise required by law, whether as a result of new information,
future events or otherwise.
Contacts
Investor Contact:
John Beck
310-203-1000
john@ritterpharma.com
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From Sep 2023 to Sep 2024